Abstract:Background: Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation, has shown efficacy and safety in a phase 3 trial involving patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation and an elevated risk of exacerbation. Whether the findings would be confirmed in a second phase 3 trial was unclear. Methods: In a phase 3, double-blind, randomized trial, we assigned patients with COPD who had a blood eosinophil count of 300 cells per microliter or higher to receive subcutaneous dupilumab (300 mg) or placebo every 2 weeks. The primary end point was the annualized rate of moderate or severe exacerbations. Key secondary end points, analyzed in a hierarchical manner to adjust for multiplicity, included the changes from baseline in the prebronchodilator forced expiratory volume in 1 second (FEV1) at weeks 12 and 52 and in the St. George's Respiratory Questionnaire (SGRQ; scores range from 0 to 100, with lower scores indicating better quality of life) total score at week 52. Results: A total of 935 patients underwent randomization: 470 were assigned to the dupilumab group and 465 to the placebo group. As prespecified, the primary analysis was performed after a positive interim analysis and included all available data for the 935 participants, 721 of whom were included in the analysis at week 52. The annualized rate of moderate or severe exacerbations was 0.86 (95% confidence interval [CI], 0.70 to 1.06) with dupilumab and 1.30 (95% CI, 1.05 to 1.60) with placebo; the rate ratio as compared with placebo was 0.66 (95% CI, 0.54 to 0.82; P<0.001). The prebronchodilator FEV1 increased from baseline to week 12 with dupilumab (least-squares mean change, 139 ml [95% CI, 105 to 173]) as compared with placebo (least-squares mean change, 57 ml [95% CI, 23 to 91]), with a significant least-squares mean difference at week 12 of 82 ml (P<0.001) and at week 52 of 62 ml (P = 0.02). No significant between-group difference was observed in the change in SGRQ scores from baseline to 52 weeks. The incidence of adverse events was similar in the two groups and consistent with the established profile of dupilumab. Conclusions: In patients with COPD and type 2 inflammation as indicated by elevated blood eosinophil counts, dupilumab was associated with fewer exacerbations and better lung function than placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; NOTUS ClinicalTrials.gov number, NCT04456673.).

Changes in Eotaxin-3 and Pulmonary and Activationregulated Chemokine Levels in Patients after Dupilumab Treatment: a Systematic Review and Meta-Analysis

The Changes of IgE Levels in Type 2 Inflammatory Diseases after Treatment of Dupilumab: a Systematic Review and Meta-Analysis

Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: an Analysis of a Randomized, Double-Blind Phase III Study

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases

Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis

Factors Associated with Dupilumab Response in Atopic Dermatitis: A Systematic Review and Meta-Analysis

Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis

The Changes of Eosinophil Counts in Patients after Treatment of Dupilumab: A Systematic Review and Meta‐analysis

Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation

The Efficacy and Safety of Dupilumab in Chinese Patients with Moderate-to-severe Atopic Dermatitis: a Randomized, Double-Blind, Placebo-Controlled Study.

Efficacy and Safety of Dupilumab in Pediatric Patients with Moderate to Severe Atopic Dermatitis: a Real-World Study

Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.

Characterization of Inflammatory Mediators and Metabolome in Interstitial Fluid Collected with Dermal Open Flow Microperfusion before and at the End of Dupilumab Treatment in Atopic Dermatitis

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab

Clinical efficacy and safety of dupilumab in the treatment of atopic dermatitis

Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study

Eosinophilia and Adverse Effects of Dupilumab for Respiratory Indications: A Real-World Setting

[Efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis]

Efficacy of dupilumab plus topical corticosteroids in children with atopic dermatitis: A meta‐analysis of randomized controlled trials

Clinical effectiveness and safety of dupilumab in patients with chronic obstructive pulmonary disease: A 7-year population-based cohort study

Dupilumab Reduces Exacerbations and FeNO Levels and Improves Asthma Control with Inhaled Corticosteroid Withdrawal: a Phase 2 Study